Literature DB >> 32486846

Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?

Theocharis Koufakis1, Symeon Metallidis2, Pantelis Zebekakis1,2, Ramzi A Ajjan3, Kalliopi Kotsa1.   

Abstract

Entities:  

Keywords:  COVID-19; SGLT2 inhibitors; diabetes; diabetic ketoacidosis

Mesh：

Substances：

Year:  2020        PMID： 32486846      PMCID： PMC7673172          DOI： 10.1177/1932296820932155

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN： 1932-2968


× No keyword cloud information.
  15 in total

Review 1.  2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.

Authors:  Francesco Cosentino; Peter J Grant; Victor Aboyans; Clifford J Bailey; Antonio Ceriello; Victoria Delgado; Massimo Federici; Gerasimos Filippatos; Diederick E Grobbee; Tina Birgitte Hansen; Heikki V Huikuri; Isabelle Johansson; Peter Jüni; Maddalena Lettino; Nikolaus Marx; Linda G Mellbin; Carl J Östgren; Bianca Rocca; Marco Roffi; Naveed Sattar; Petar M Seferović; Miguel Sousa-Uva; Paul Valensi; David C Wheeler
Journal:  Eur Heart J       Date:  2020-01-07       Impact factor: 29.983

2.  SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats.

Authors:  Masanori Yokono; Toshiyuki Takasu; Yuka Hayashizaki; Keisuke Mitsuoka; Rumi Kihara; Yuko Muramatsu; Sousuke Miyoshi; Atsuo Tahara; Eiji Kurosaki; Qun Li; Hiroshi Tomiyama; Masao Sasamata; Masayuki Shibasaki; Yasuo Uchiyama
Journal:  Eur J Pharmacol       Date:  2014-01-30       Impact factor: 4.432

Review 3.  Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.

Authors:  Milton Packer
Journal:  Diabetes Obes Metab       Date:  2018-02-20       Impact factor: 6.577

Review 4.  Biology of human sodium glucose transporters.

Authors:  Ernest M Wright; Donald D F Loo; Bruce A Hirayama
Journal:  Physiol Rev       Date:  2011-04       Impact factor: 37.312

5.  Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.

Authors:  Purva V Sharma; Yash B Jobanputra; Karen Lewin; Stuart Bagatell; Daniel M Lichtstein
Journal:  Rev Recent Clin Trials       Date:  2018

6.  Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.

Authors:  Aurora Merovci; Carolina Solis-Herrera; Giuseppe Daniele; Roy Eldor; Teresa Vanessa Fiorentino; Devjit Tripathy; Juan Xiong; Zandra Perez; Luke Norton; Muhammad A Abdul-Ghani; Ralph A DeFronzo
Journal:  J Clin Invest       Date:  2014-01-27       Impact factor: 14.808

Review 7.  Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications.

Authors:  J E Gerich
Journal:  Diabet Med       Date:  2010-02       Impact factor: 4.359

8.  2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  John B Buse; Deborah J Wexler; Apostolos Tsapas; Peter Rossing; Geltrude Mingrone; Chantal Mathieu; David A D'Alessio; Melanie J Davies
Journal:  Diabetes Care       Date:  2019-12-19       Impact factor: 17.152

9.  Sodium-glucose cotransporter 2 inhibitors improved time-in-range without increasing hypoglycemia in Japanese patients with type 1 diabetes: A retrospective, single-center, pilot study.

Authors:  Daisuke Suzuki; Hodaka Yamada; Masashi Yoshida; Shunsuke Funazaki; Misato Amamoto; Jun Morimoto; Kazuo Hara
Journal:  J Diabetes Investig       Date:  2020-03-27       Impact factor: 4.232

10.  Diabetes is a risk factor for the progression and prognosis of COVID-19.

Authors:  Weina Guo; Mingyue Li; Yalan Dong; Haifeng Zhou; Zili Zhang; Chunxia Tian; Renjie Qin; Haijun Wang; Yin Shen; Keye Du; Lei Zhao; Heng Fan; Shanshan Luo; Desheng Hu
Journal:  Diabetes Metab Res Rev       Date:  2020-03-31       Impact factor: 4.876
View more
  5 in total

1.  Hospital Diabetes Meeting 2022.

Authors:  Jingtong Huang; Andrea M Yeung; Kevin T Nguyen; Nicole Y Xu; Jean-Charles Preiser; Robert J Rushakoff; Jane Jeffrie Seley; Guillermo E Umpierrez; Amisha Wallia; Andjela T Drincic; Roma Gianchandani; M Cecilia Lansang; Umesh Masharani; Nestoras Mathioudakis; Francisco J Pasquel; Signe Schmidt; Viral N Shah; Elias K Spanakis; Andreas Stuhr; Gerlies M Treiber; David C Klonoff
Journal:  J Diabetes Sci Technol       Date:  2022-07-29

Review 2.  Novel Molecular Evidence Related to COVID-19 in Patients with Diabetes Mellitus.

Authors:  Yu-Huang Liao; Jing-Quan Zheng; Cai-Mei Zheng; Kuo-Cheng Lu; You-Chen Chao
Journal:  J Clin Med       Date:  2020-12-07       Impact factor: 4.241

Review 3.  Perspectives of Antidiabetic Drugs in Diabetes With Coronavirus Infections.

Authors:  Bao Sun; Shiqiong Huang; Jiecan Zhou
Journal:  Front Pharmacol       Date:  2021-01-29       Impact factor: 5.810

Review 4.  COVID-19 in Relation to Hyperglycemia and Diabetes Mellitus.

Authors:  Hayder M Al-Kuraishy; Ali I Al-Gareeb; M Alblihed; Susana G Guerreiro; Natália Cruz-Martins; Gaber El-Saber Batiha
Journal:  Front Cardiovasc Med       Date:  2021-05-20

5.  Metformin Use in Relation to Clinical Outcomes and Hyperinflammatory Syndrome Among COVID-19 Patients With Type 2 Diabetes: A Propensity Score Analysis of a Territory-Wide Cohort.

Authors:  Carlos K H Wong; David T W Lui; Angel Y C Lui; Marshall C H Low; Ashley C Y Kwok; Kristy T K Lau; Ivan C H Au; Xi Xiong; Matthew S H Chung; Eric H Y Lau; Benjamin J Cowling
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-07       Impact factor: 5.555
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.